An Observer-Blinded, Placebo-Controlled, Multiple-Ascending, Dose-Escalation Study to Explore the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeat Intravenous Administrations of UTTR1147A in Healthy Volunteers and Patients With Ulcerative Colitis and Crohn's Disease
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2018
At a glance
- Drugs RG 7880 (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Genentech
- 29 Jan 2018 Planned number of patients changed from 45 to 90.
- 16 Oct 2017 Planned End Date changed from 27 Oct 2017 to 7 Feb 2020.
- 16 Oct 2017 Planned primary completion date changed from 27 Oct 2017 to 7 Feb 2020.